Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-19T15:09:27.519Z Has data issue: false hasContentIssue false

1790 – Impact Of a New Antidepressant Drug Treatment On The Occurrence Of An Antipsychotic Prescription In The General Population

Published online by Cambridge University Press:  15 April 2020

M. Tournier
Affiliation:
Université Bordeaux Segalen, Bordeaux, France INSERM U657, Bordeaux, France Centre Hospitalier Charles Perrens, Bordeaux, France
M. André
Affiliation:
INSERM U657, Bordeaux, France
Y. Gaudron
Affiliation:
INSERM U657, Bordeaux, France
B. Bégaud
Affiliation:
Université Bordeaux Segalen, Bordeaux, France INSERM U657, Bordeaux, France CHU de Bordeaux, Bordeaux, France
H. Lepouriel
Affiliation:
INSERM U657, Bordeaux, France
H. Verdoux
Affiliation:
Université Bordeaux Segalen, Bordeaux, France INSERM U657, Bordeaux, France Centre Hospitalier Charles Perrens, Bordeaux, France

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

An antidepressant drug treatment (ADT) may be associated with adverse effects such as manic switch or chronic irritable dysphoria. These adverse effects have been highlighted in patients with bipolar disorder but never in the general population. They may lead to prescription of sedative treatment, particularly antipsychotic drugs.

Objectives

To assess whether the prescription of ADT is subsequently associated with an increased probability of prescription of an antipsychotic treatment, in the general population.

Methods

A nested case-control study was carried out in a cohort of subjects initiating a new ADT registered in the national insurance database (n = 28,145). Cases were defined as subjects receiving a new antipsychotic drug treatment. Controls did not receive any antipsychotic drug until the index date. They were compared for the probability of receiving an ADT during at least two weeks in the four weeks prior to antipsychotic initiation.

Results

2558 subjects received an new antipsychotic drug over the follow up. After adjustment for gender, age, chronic disease status, welfare benefit, specialty of the ADT prescriber, co-prescription of other psychotropic drugs, a new antipsychotic dispensing was associated with exposure to ADT during at least two weeks in the four weeks (OR 1,42 ; IC95% 1,29-1,58 ; p < 0,0001).

Conclusions

The dispensing of ADT increases the risk of receiving an antipsychotic treatment, which may be a proxy for manic switch, in the general population.

Type
Abstract
Copyright
Copyright © European Psychiatric Association 2013
Submit a response

Comments

No Comments have been published for this article.